Hypertension is often described in simple terms: a chronic condition in which blood pressure remains persistently elevated. Yet behind those numbers o.

Barclays started coverage of Regeneron Pharmaceuticals with an Overweight rating and a $923 price target, saying the company’s shares undervalue near- and medium-term profit growth from Dupixent and ...

A growing body of research now links the trillions of microbes living in the human gut to how well people age, with recent studies identifying specific bacterial signatures that distinguish healthy ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.

GAIA, Daiichi Sankyo Europe partner to commercialize next-generation digital therapeutic ‘lipodia’ for cardiovascular care: Hamburg Saturday, March 7, 2026, 12:00 Hrs [IST] GA ...

Detailed price information for Aptevo Therapeutics Inc (APVO-Q) from The Globe and Mail including charting and trades.

HUTCHMED divested a 45.0% equity interest in SHPL for $608.5 million in cash in April 2025, retaining a 5.0% equity interest. As a result, HUTCHMED’s share of equity in earnings of SHPL in 2025 ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM ESTCompany ParticipantsJean-Paul Kress - Chairman ...